Vincerx Pharma Announces Creation of its Scientific Advisory Board

Vincerx Pharma, Inc. has announced the formation of a Scientific Advisory Board in an effort to advance their clinical pipeline. Vincerx is a biopharmaceutical company which aspires to conquer cancer with innovative therapies.

Their research revolves around inhibiting PTEFb phosphorylation of RNA polymerase II (RNAPII). As complex as that sounds, it comes down to preventing the creation and expression of cancer driving genes. VIP152, an IV administered pharmaceutical, has advanced into phase 1 clinical trials. Vincerx is working on 4 other pharmaceuticals simultaneously. One is an oral follow-up to VIP152 – both target solid tumors. The other three focus on a different approach – bioconjugation – to tackle leukemia, B-cell malignancies, and multiple solid tumors.

The board is composed of world leading academics and industry leaders in cancer research and therapeutics. John C. Byrd, M.D. has been appointed chairman of the board. His expertise, along with the other 7 other members, will hopefully help the advancement of the diverse clinical pipeline.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts